Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
SEPN is expected to report earnings to rise 289.47% to -74 cents per share on August 17
Q2'26
Est.
$-0.74
Q1'26
Beat
by $0.55
Q4'25
Beat
by $0.48
Q3'25
Beat
by $0.83
Q2'25
Beat
by $0.07
The last earnings report on May 11 showed earnings per share of -18 cents, beating the estimate of -74 cents. With 106.33K shares outstanding, the current market capitalization sits at 1.35B.